Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines. It markets two medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. It is also markets a diabetes treatment, BYDUREON (exenatide extended-release for injectable suspension). BYDUREON is an extended-release medication for type 2 diabetes that provides continuous glycemic control in a once-weekly dose. Amylin maintains a research and early development program focused on peptide and protein therapeutics. It has also entered into alliances and business initiatives, including its relationship with Biocon, Limited (Biocon) to develop pharmaceutical products, including AC165198, a peptide hybrid drug candidate for diabetes, which was developed from its phybrid technology platform. In August 2012, Bristol-Myers Squibb Company acquired the Company.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-858-5522200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Amylin Pharmaceuticals (NASDAQ:AMLN) Frequently Asked Questions
What is Amylin Pharmaceuticals' stock symbol?
Amylin Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLN."
Has Amylin Pharmaceuticals been receiving favorable news coverage?
Media stories about AMLN stock have trended somewhat positive on Monday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amylin Pharmaceuticals earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Amylin Pharmaceuticals?
Shares of AMLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amylin Pharmaceuticals' official website?
How can I contact Amylin Pharmaceuticals?
Amylin Pharmaceuticals' mailing address is 9360 Towne Centre Dr Ste 110, SAN DIEGO, CA 92121-3030, United States. The biopharmaceutical company can be reached via phone at +1-858-5522200.
MarketBeat Community Rating for Amylin Pharmaceuticals (NASDAQ AMLN)
MarketBeat's community ratings are surveys of what our community members think about Amylin Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
